Xencor disclosed that its Phase 1 study of XmAb942, a long‑acting anti‑TL1A antibody for inflammatory bowel disease, met its primary endpoints and that the data were presented on May 4, 2026 at Digestive Disease Week in Chicago.
The study’s success supports a best‑in‑class drug profile and informs the ongoing Phase 2b XENITH‑UC trial, positioning XmAb942 for potential regulatory submission. CEO Bassil Dahiyat noted that the Phase 1 data validate the design goals, combining high potency with a convenient dosing schedule of a single subcutaneous injection every 12 weeks, which could improve patient convenience and adherence.
Xencor’s financial footing remains strong, with $611 million in cash and marketable securities expected to fund operations through 2028. The company’s market capitalization was approximately $940.7 million as of May 4, 2026.
The presentation at DDW strengthens Xencor’s pipeline, which also includes XmAb412, a TL1A × IL23p19 bispecific antibody slated to enter first‑in‑human studies in Q3 2026.
The data reinforce Xencor’s strategy to leverage its proprietary XmAb technology platform, enhancing antibody half‑life and potency, and may give the company a competitive edge in the growing TL1A therapeutic space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.